Stemtech (STEK) Stock Overview
A stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
STEK Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Stemtech Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0035 |
| 52 Week High | US$0.065 |
| 52 Week Low | US$0.0033 |
| Beta | 2.28 |
| 1 Month Change | -73.08% |
| 3 Month Change | -87.93% |
| 1 Year Change | -87.01% |
| 3 Year Change | -98.87% |
| 5 Year Change | n/a |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| STEK | US Personal Products | US Market | |
|---|---|---|---|
| 7D | -47.8% | -4.5% | 0.5% |
| 1Y | -87.0% | -13.0% | 20.1% |
Return vs Industry: STEK underperformed the US Personal Products industry which returned -13% over the past year.
Return vs Market: STEK underperformed the US Market which returned 20.1% over the past year.
Price Volatility
| STEK volatility | |
|---|---|
| STEK Average Weekly Movement | 26.7% |
| Personal Products Industry Average Movement | 8.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: STEK's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: STEK's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Charles Arnold | www.stemtech.com |
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. The company’s products enhance and support the work of the body’s stem cells by releasing more stem cells, helping to circulate them in the blood, and migrate them into tissues, where they can perform their daily function of renewal for optimal health. It offers rapid renew stem cell peptide night cream under the RCM System, stemrelease3, Stemflo MigraStem, OraStem, and Collect One brand name, as well as Cellect One shield hypochlorous acid skin care product.
Stemtech Corporation Fundamentals Summary
| STEK fundamental statistics | |
|---|---|
| Market cap | US$655.19k |
| Earnings (TTM) | -US$3.32m |
| Revenue (TTM) | US$3.91m |
Is STEK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STEK income statement (TTM) | |
|---|---|
| Revenue | US$3.91m |
| Cost of Revenue | US$942.49k |
| Gross Profit | US$2.97m |
| Other Expenses | US$6.29m |
| Earnings | -US$3.32m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 75.90% |
| Net Profit Margin | -84.86% |
| Debt/Equity Ratio | -77.5% |
How did STEK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 17:17 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stemtech Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.